News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
